{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:42:27Z","timestamp":1778002947409,"version":"3.51.4"},"reference-count":65,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,7,28]],"date-time":"2005-07-28T00:00:00Z","timestamp":1122508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Neurochemistry"],"published-print":{"date-parts":[[2005,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several multifunctional iron chelators have been synthesized from hydroxyquinoline pharmacophore of the iron chelator, VK\u201028, possessing the monoamine oxidase (MAO) and neuroprotective<jats:italic>N<\/jats:italic>\u2010propargylamine moiety. They have iron chelating potency similar to desferal. M30 is a potent irreversible rat brain mitochondrial MAO\u2010A and \u2010B inhibitor<jats:italic>in\u2003vitro<\/jats:italic>(IC<jats:sub>50<\/jats:sub>, MAO\u2010A, 0.037\u2003\u00b1\u20030.02; MAO\u2010B, 0.057\u2003\u00b1\u20030.01). Acute (1\u20135\u2003mg\/kg) and chronic [5\u201310\u2003mg\/kg intraperitoneally (i.p.) or orally (p.o.) once daily for 14\u2003days]<jats:italic>in\u2003vivo<\/jats:italic>studies have shown M30 to be a potent brain selective (striatum, hippocampus and cerebellum) MAO\u2010A and \u2010B inhibitor. It has little effects on the enzyme activities of the liver and small intestine. Its N\u2010desmethylated derivative, M30A is significantly less active. Acute and chronic treatment with M30 results in increased levels of dopamine (DA), serotonin(5\u2010HT), noradrenaline (NA) and decreases in DOPAC (dihydroxyphenylacetic acid), HVA (homovanillic acid) and 5\u2010HIAA (5\u2010hydroxyindole acetic acid) as determined in striatum and hypothalamus. In the mouse MPTP (<jats:italic>N<\/jats:italic>\u2010methy\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine) model of Parkinson's disease (PD) it attenuates the DA depleting action of the neurotoxin and increases striatal levels of DA, 5\u2010HT and NA, while decreasing their metabolites. As DA is equally well metabolized by MAO\u2010A and \u2010B, it is expected that M30 would have a greater DA neurotransmission potentiation in PD than selective MAO\u2010B inhibitors, for which it is being developed, as MAO\u2010B inhibitors do not alter brain dopamine.<\/jats:p>","DOI":"10.1111\/j.1471-4159.2005.03341.x","type":"journal-article","created":{"date-parts":[[2005,9,9]],"date-time":"2005-09-09T10:06:49Z","timestamp":1126260409000},"page":"79-88","source":"Crossref","is-referenced-by-count":165,"title":["Novel multifunctional neuroprotective iron chelator\u2010monoamine oxidase inhibitor drugs for neurodegenerative diseases.<i>In\u2003vivo<\/i>selective brain monoamine oxidase inhibition and prevention of MPTP\u2010induced striatal dopamine depletion"],"prefix":"10.1111","volume":"95","author":[{"given":"Shunit","family":"Gal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mati","family":"Fridkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moussa B. H.","family":"Youdim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,8,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(96)00606-6"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01047.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02425.x"},{"key":"e_1_2_7_6_1","first-page":"251","article-title":"Selectivity of melaninized nigra\u2010striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron\u2010melanin interaction","volume":"29","author":"Ben\u2010Shachar D.","year":"1990","journal-title":"J. Neural Transm. Suppl."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1991.tb11444.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm031087c"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91940-7"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.03.005"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(89)91530-8"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1989.tb07264.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1989.tb09133.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(02)00216-2"},{"key":"e_1_2_7_15_1","first-page":"495","article-title":"Pharmacology of rasagiline (N\u2010propargyl\u20101R\u2010aminoindan)","volume":"1999","author":"Finberg J. P.","year":"1999","journal-title":"Adv. Neurol."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.01923.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1471-4159.1994.63030793.x","article-title":"Altered brain metabolism of iron as a cause of neurodegenerative diseases?","volume":"793","author":"Gerlach M.","year":"1994","journal-title":"J. Neurochem."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1977.tb07506.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0212-1"},{"key":"e_1_2_7_20_1","first-page":"217","article-title":"Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP","volume":"32","author":"Heikkila R. E.","year":"1990","journal-title":"J. Neural Transm. Suppl."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00929-7"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199914020-00004"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02252926"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1992.tb08362.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_3.161S"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1981.tb16771.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00126-0"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(76)90290-3"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1996.67041532.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01277665"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01291883"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1306.021"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","DOI":"10.1111\/j.1471-4159.2004.02503.x","article-title":"Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (\u2010)\u2010epigallocatechin\u20103\u2010gallate: implications for neurodegenerative diseases","author":"Mandel S.","year":"2004","journal-title":"J. Neurochem."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(00)00144-5"},{"key":"e_1_2_7_35_1","first-page":"171","article-title":"Neurotoxins induce apoptosis in dopamine neurons: protection by N\u2010propargylamine\u20101(R)\u2010 and (S)\u2010aminoindan, rasagiline and TV1022","volume":"60","author":"Maruyama W.","year":"2002","journal-title":"J. Neural Transm. Suppl."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(03)00211-8"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(85)91451-9"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90462-6"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00500765"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)90833-8"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(85)90229-0"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1989.tb09150.x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.18.9866"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050182"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-002-0827-z"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1994.62010134.x"},{"key":"e_1_2_7_49_1","first-page":"441","volume-title":"Methods in Biogenic Amine Ressearch.","author":"Tipton K. F.","year":"1983"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1306.014"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-1916fje"},{"key":"e_1_2_7_52_1","first-page":"157","article-title":"TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease","volume":"60","author":"Weinstock M.","year":"2000","journal-title":"J. Neural Transm. Suppl."},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(02)00176-4"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0078fje"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.3.6.737"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.11.007"},{"key":"e_1_2_7_57_1","volume-title":"Encyclopedia of Neuroscience","author":"Youdim M. B. H.","year":"2004"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-813X(03)00103-7"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080102"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703826"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2001.tb03656.x"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-004-0143-x"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1306.025"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1537"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2004.10.037"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03340.x"}],"container-title":["Journal of Neurochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1471-4159.2005.03341.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1471-4159.2005.03341.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T14:47:13Z","timestamp":1706539633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-4159.2005.03341.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,25]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.1111\/j.1471-4159.2005.03341.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03341.x","archive":["Portico"],"relation":{},"ISSN":["0022-3042","1471-4159"],"issn-type":[{"value":"0022-3042","type":"print"},{"value":"1471-4159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,25]]}}}